# Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)

> **NCT05621707** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinomas
- Concurrent Chemoradiotherapy
- Immunotherapy
- Chemotherapy

## Interventions

- **DRUG:** chemotherapy combined with PD-1 inhibitors

## Key facts

- **NCT ID:** NCT05621707
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-02
- **Primary completion:** 2026-10
- **Final completion:** 2026-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05621707

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05621707, "Chemoradiotherapy Following Immunotherapy Plus Chemotherapy for Locally-advanced Esophageal Squamous Cell Cancer (RICE)". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05621707. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*